Supplementary Table 2.
Parameters of patients treated with hydroxyurea versus those not treated.
| Parameter | Patients receiving HU (n=27) | Patients not receiving HU (n=35) | P-value |
|---|---|---|---|
|
| |||
| Hemoglobin (g/dl) ) mean ± SD | 9.074± 0.569 | 8.011±0.698 | <0.0001 |
|
| |||
| Ferritin levels at steady state(ng\dl); (Mean ± SD) | 171.89±54.48 | 152.51±51.63 | 0.158 |
|
| |||
| Energy intake (kcal/day); (Mean ± SD) | 1889.953±104.726 | 1724.158±92.551 | < 0.0001 |
|
| |||
| Daily protein intake (g); mean ± SD | 50.42±13.48 | 46.16±11.94 | 0.192 |
|
| |||
| Plasma folate level (ng/mL); mean ± SD | 14.86±2.98 | 13.28±3.11 | 0.048* |
|
| |||
| Serum zinc ( mg/dl ; mean ± SD | 70.68±12.59 | 61.65±14.02 | 0.011* |
|
| |||
| Vitamin B12 (pg/ml) ; mean ± SD | 339.894±84.474 | 287.651±82.173 | 0.017* |
|
| |||
| 25-OH-vitamin D (ng/mL); mean ± SD | 20.94±4.82 | 16.16±3.21 | < 0.0001** |
|
| |||
| - Growth hormone (ng/ml); mean±SD | 6.79± 2.12 | 4.24±2.52 | 0.402 |
|
| |||
| - Hypothyroid, n (%) | 5 (25) | 17 (40.48). | 0.223 |
| - Euothyroid, n (%) | 10 (50) | 14 (33.33) | 0.21 |
| - Hyperthyroid; n (%) | 5 (25) | 11 (26.19) | 0.921 |
|
| |||
| - Testesterone (ng/dL) (in men); mean ±SD | 656.12±205.84 | 603.91±185.49 | 0.321 |
|
| |||
| Estradiol (pg/mL) - (in women) |
200.29±66.72 | 189.68±71.53 | 0.579 |
|
| |||
| Mean number of SCD-related crises that needed hospitalization/person/during the entire follow-up | 4.33±1.65 | 8.76±2.44 | <0.0001** |
|
| |||
| Incidence rate of SCD-related events that required hospitalization (cases per person-year); (95% CI); | 0.328 (0.258 to 0.410) | 0.508 (0.425 to 0.601) | 0.0021** |
|
| |||
| Mean SCD severity score during follow-up | 0.215±0.116 | 0.440±0.177 | < 0.0001** |